Merck

MRK

Market cap $315B

Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio.

Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.

The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.

Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.

Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reportedly neared an agreement to acquire a psychedelics company.

Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.

Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Merck & Co Inc.'s (NYSE:MRK) LIPFENDRA (enlicitide) as an adjunct to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).

The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with ​hereditary forms of the disease, which causes elevated levels of LDL.

Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.